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Abstract 
HEPATIC INSULIN RECEPTOR TYROSINE KINASE ACTIVITY IN 
DIABETES: MODULATION BY ASSORTED ADENOSINE TRIPHOS¬ 
PHATASES/PHOSPHATASES WHICH COPURIFY IN PARTIALLY 
PURIFIED PREPARATIONS OF THE INSULIN RECEPTOR. Darrick 
J. Alaimo, Arthur I. Salhanick, and John M. Amatruda. Endocrine- 
Metabolism Unit, Department of Internal Medicine, University of 
Rochester School of Medicine and Dentistry, Rochester, New York. 
(Sponsored by Robert Sherwin, Department of Internal Medicine, Yale 
University School of Medicine). 
We evaluated the assay conditions for quantifying insulin receptor 
tyrosine kinase activation by insulin toward poly Glu/Tyr(4:l) in hepatic 
plasma membrane and microsomal wheat-germ agglutinin eluates 
prepared from normal and streptozotocin diabetic rats. Optimal insulin 
receptor tyrosine kinase conditions were found to include HEPES buffer, the 
absence of cytosine triphosphate, and the presence of sodium orthovanadate 
(1 mM) and para-nitrophenylphosphate (10 mM). Using Lineweaver-Burke 
analysis, the maximum insulin receptor tyrosine kinase activity was 
demonstrated to be reduced by 43% (6.37 and 3.64 pmol 32p incorporated/ 
fmol insulin binding for control and diabetic preparations, respectively) in 
plasma membranes and by 42% (6.80 and 3.97 pmol 32p incorporated/fmol 
insulin binding for control and diabetic groups, respectively) in microsomes 
from diabetic rats. Quantitation of 32p.orthophosphate generation during 
incubations with [y32p]ATP revealed the presence of ATPase/phosphatase 
activity that copurified with insulin receptors from wheat-germ agglutinin 

columns. This activity was present in preparations from plasma mem¬ 
branes and microsomes and had a vanadate-insensitive component in 
plasma membrane insulin receptor preparations. The decreased tyrosine 
kinase activity found in preparations from diabetic rats cannot be explained 
by this ATPase/phosphatase activity which was found to be lower (35-48%) 
in diabetic preparations. 
The results provide the first evidence that the insulin resistance of 
nonketotic diabetes mellitus is associated with a reduction in hepatic 
plasma membrane insulin receptor tyrosine kinase and describe the 
presence of a copurifying ATPase/phosphatase activity. The mechanisms 
underlying the decrease in insulin receptor kinase in diabetes and the 
possible physiologic role for this copurifying ATPase/phosphatase activity 
require further investigation. 
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The insulin receptor is a transmembrane glycoprotein composed of two 
a-subunits and two P-subunits that are held together by disulfide bonds 
(reviewed in 1). The a-subunits are highly glycosylated, extramembrane 
peptides that bind insulin, while the P-subunits are glycosylated, trans¬ 
membrane peptides that have intrinsic tyrosine kinase activity (1). The 
cloning of the insulin receptor gene has led to further definition of the 
structure of the insulin receptor. The p-subunit has been found to contain a 
tyrosine kinase domain that has a high degree of homology to other known 
tyrosine kinases such as the src oncogene, the epidermal growth factor 
(EGF) receptor, and the platelet-derived growth factor (PDGF) receptor 
(reviewed in 2,3). The p-subunit also has an adenosine triphosphate (ATP) 
binding region that appears to be necessary for tyrosine kinase activity (4,5). 
The insulin receptor is responsible for mediating all of the biological 
effects of insulin. Short-term effects occur within minutes and include 
stimulation of nutrient uptake, glycolysis, glycogenesis, lipogenesis, and 
inhibition of lipolysis and gluconeogenesis (reviewed in 5). Long term 
effects occur over hours and include stimulation of cell growth, DNA 
synthesis, and protein synthesis (5). Certain effects of insulin will pre¬ 
dominate in the cells of different organ systems (reviewed in 7). Liver and 
muscle cells are highly responsive to insulin’s effects on gluconeogenesis, 
glycogenesis, and nutrient uptake, while adipocytes are more responsive to 
insulin's effects on lipolysis and lipogenesis. 
The first step in insulin's action on a target cell is its binding to the a- 
subunit of the insulin receptor (1). The signal is transduced by an 
unknown mechanism, possibly by receptor clustering, that activates the 
■ 
2 
tyrosine kinase domain of the (3-subunit (7). The (3-subunit autophospho- 
rylates to a tri-phosphorylated form in the tyrosine-1150 domain which is 
required for the tyrosine kinase to phosphorylate endogenous substrates 
(2,9,10). Although the phosphorylation of numerous endogenous 
uncharacterized proteins has been described (6,7,11,12,13), their relation to 
intracellular signaling and insulin's actions remains to be elucidated. 
By unknown means, intracellular signals activate a variety of 
mechanisms which mediate the effects of insulin. For example, 
enhancement of glucose transport is mediated by translocation of a glucose 
transporter protein (glut-4) to the plasma membrane (PM) from 
intracellular storage vesicles (6,14). Metabolic effects of insulin could be the 
result of altering the activity of various kinases and phosphatases that are 
involved in controlling the activity of regulatory enzymes of metabolism (6). 
Another example of an intracellular effect of insulin is its effect on cell 
growth which occurs via alterations in the rates of DNA replication and 
transcription (6,7). 
Many theories exist regarding the mechanisms by which insulin 
binding results in intracellular signaling. Some theories revolve around 
G-proteins (3,4). G-proteins are a group of intramembrane proteins that 
are involved in coupling certain receptors to their second messenger 
systems (i.e. (3-adrenergic receptors coupled to adenylate cyclase via the 
G-protein, Gg). Although there are a number of different types of G- 
proteins, they all require the hydrolysis of guanosine triphosphate (GTP) for 
signal transduction to occur (4). Houslay (3) has suggested that a unique 
G-protein (Gins) is involved in insulin-stimulated inhibition of adenylate 
cyclase because GTP is required. He also has argued for Gins involvement 
in insulin activated cyclic adenosine monophosphate (cAMP) 
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phosphodiesterase (PDE) which requires GTP and can also be activated by 
Cholera toxin, an activator of G-proteins. The insulin receptor tyrosine 
kinase can phosphorylate G-protein subunits in vitro, and this ability could 
be a mechanism of interaction (3). Further evidence has come from a study 
(15) using streptozotocin-induced diabetic rats which showed that diabetic 
liver tissue had a loss in both amount and activity of Gi (a different type of 
G-protein) that was reversed by insulin administration. These results 
suggested that insulin regulates the expression of Gi in the liver. Because 
Gi mediates inhibition of adenylate cyclase and may couple receptors to 
potassium channels, decreased expression of Gi may be responsible in part 
for some of the physiologic changes found in diabetes (15). 
Some evidence has accumulated for a role for the calcium-calmodulin 
second messenger system in the intracellular mechanism of action of 
insulin. In this second messenger system, an activated receptor system 
increases intracellular calcium concentration. Calcium then binds to the 
protein calmodulin creating a complex which activates a number of 
different calmodulin-sensitive enzymes (6). Calmodulin is phosphorylated 
at a tyrosine residue in the calcium binding region by the activated insulin 
receptor tyrosine kinase which could alter the activity of calmodulin (6). 
Insulin enhances calmodulin binding to adipocyte plasma membranes 
which may be related to the insulin-induced inhibition of a calmodulin- 
sensitive adenosine triphosphatase (ATPase) found in plasma membranes 
(2). There is evidence for calcium and calmodulin binding sites on the 
(3-subunit of the insulin receptor, and these sites may be involved in 
regulation of insulin receptor autophosphorylation (2). 
Internalization of insulin bound to its receptor also seems to be 
important in mediating the actions of insulin on various cellular processes. 
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Internalization occurs either by the clathrin coated pit pathway (10%) or by 
direct internalization via the non-coated pit pathway, and there are binding 
sites for insulin on most organelles (2,7). Inhibition of insulin receptor 
internalization and processing has been shown to inhibit a number of 
effects of insulin including stimulation of glucose transport, regulation of 
glycogen metabolism, and effects on RNA processing (2). Insulin and its 
receptor have been localized in nuclear membranes where insulin has been 
shown to activate a RNA-dependent nucleoside triphosphatase that 
provides energy to transport large molecules through nucleopores (2). 
Insulin may regulate messenger RNA efflux from the nucleus by this 
mechanism and thus influence protein synthesis (2). However, by using a 
mutated receptor, McClain has shown that the noninternalizing insulin 
receptor is fully capable of activating glycogen synthetase and stimulating 
mitosis in growth-arrested cells (16). 
Other researchers have concentrated on the phosphatidylinositol 
second messenger pathway while studying the intracellular mechanism of 
action of insulin. In this second messenger system, an activated receptor 
system stimulates a phospholipase which cleaves phosphatidylinositol, an 
intramembrane phosphoglycolipid, to form inositol triphosphate and 
diacylglycerol (DAG). Inositol triphosphate stimulates the release of 
calcium from intracellular stores, while DAG activates Protein Kinase-C 
(PK-C) (6). The insulin receptor tyrosine kinase has been shown to 
stimulate phosphatidylinositol kinase, an enzyme involved in the synthesis 
of phosphatidylinositol, via phosphorylation (6,11), but no changes in 
inositol triphosphate or phosphatidylinositol levels have been found (6). 
Insulin has been shown to stimulate DAG synthesis (2,14), but changes in 
turnover have not been observed (2). Some studies have shown that insulin 
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has no effect on PK-C activity (2), while a recent study by Cherqui et al. (14) 
has provided evidence for myristoyl-DAG and PK-C involvement in insulin- 
stimulated glucose uptake. Their study showed that cells transfected with 
insulin receptor genes that were mutated at tyrosine residues 1162 and 1163 
(major sites of autophosphorylation) had decreased tyrosine kinase activity 
and 2-deoxyglucose uptake. In addition, the concentration-dose response 
curves for insulin-stimulated myristoyl-DAG production and 2-deoxy¬ 
glucose uptake were superimposable in both normal and mutant cells. 
They also showed that insulin-stimulated phosphorylation of a 40 kDa 
protein (a known substrate for PK-C) was diminished in the mutant cells. 
However, direct stimulation of PK-C could stimulate phosphorylation of the 
40 kDa protein and uptake of 2-deoxyglucose in mutant cells to near control 
levels. Thus, tyrosines 1162 and 1163 may control glucose uptake, at least in 
part, via myristoyl-DAG production and PK-C activation. 
Related to the phosphatidylinositol system are studies that have 
concentrated on inositol phosphate glycans as mediators of insulin action. 
Insulin has been shown to stimulate (possibly via a G-protein) a specific 
phospholipase-C that liberates inositol phosphate glycans from PM 
phosphoglycolipids (2,6,7,11). Phospholipase-C may also release DAG with 
inositol phosphate glycans (6). Inositol phosphate glycans have been shown 
to inhibit adenylate cyclase and to stimulate cAMP PDE and thus may be 
involved in regulation of cAMP levels by insulin (6). These mediators are 
also able to stimulate liver pyruvate dehydrogenase activity (6). Thus, 
inositol phosphate glycans may be involved in some of insulin's actions. 
However, some investigators have been unable to confirm the existence of 
these mediators (6). 
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Although it is evident from the above discussion that multiple signaling 
pathways are involved in insulin action, increasing evidence suggests that 
the tyrosine kinase activity of the insulin receptor is involved in signal 
transmission. Insulin mimetic agents, such as concanavalin A, have been 
shown to increase insulin receptor tyrosine kinase activity (1). Agents that 
inhibit the insulin receptor tyrosine kinase have also been useful. 
Catecholamines and phorbol esters were shown to inhibit insulin- 
stimulated autophosphorylation, tyrosine kinase activity, and glucose 
transport in isolated human adipocytes (17). Synthetic competitive 
inhibitors of tyrosine kinases have been shown to inhibit insulin-stimulated 
antilipolysis and lipogenesis (18). 
Studies with antireceptor antibodies have been more equivocal. 
Antibodies against the tyrosine kinase domain of the (3-subunit inhibit some 
of insulin's actions (6), while a different antibody directed against the 
(3-subunit has been shown to enhance insulin receptor tyrosine kinase 
activity and to stimulate 2-deoxyglucose transport, lipogenesis, and 
glycogen synthesis in isolated cells in a manner that was not additive to the 
effect of insulin (19). Other antibodies against the a-subunit have been 
shown to stimulate amino acid (20) and glucose (21) uptake in isolated cells 
without stimulating insulin receptor autophosphorylation or tyrosine 
kinase activity (20,21). These studies argued against an obligatory role for 
the insulin receptor tyrosine kinase in the transmembrane signaling to 
mediate all of insulin's actions. However, a study (4) using site-directed 
mutagenesis showed that the replacement of lysine residue 1030 in the 
putative ATP-binding domain of the insulin receptor abolished insulin- 
stimulated autophosphorylation, tyrosine kinase activity, and 
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2-deoxyglucose uptake. Interestingly, this mutation also prevented the 
stimulation of 2-deoxyglucose uptake by various antireceptor antibodies that 
had been previously shown to stimulate glucose uptake independent of 
autophosphorylation or tyrosine kinase activity. 
Further studies with site-directed mutations of the insulin receptor 
have also suggested that the insulin receptor kinase is involved in 
mediating many but not all of insulin’s actions. Studies using insulin 
receptors mutated in the ATP-binding domain and thus deficient in kinase 
activity have shown that the mutated cells also have impaired insulin- 
dependent 2-deoxyglucose uptake (4,5), S6 kinase activity, endogenous 
substrate phosphorylation, glycogen synthesis, and DNA synthesis (5). 
Site-directed mutation of tyrosine 960 did not affect autophosphorylation or 
tyrosine kinase activity toward exogenous substrates but did inhibit insulin- 
stimulated glycogen synthesis, amino acid uptake, DNA synthesis, and 
phosphorylation of an endogenous substrate (pp 185) (22). This study 
suggested that autophosphorylation was not sufficient to mediate some 
actions of insulin and that tyrosine phosphorylation of cellular substrates 
(which may involve tyrosine 960) was needed for signal transduction (22). 
As discussed above, site-directed mutations at major sites of autophos¬ 
phorylation (tyrosines 1162 and 1163) result in diminshed tyrosine kinase 
activity, but the decrease in 2-deoxyglucose uptake may be more related to 
alterations in autophosphorylation, DAG production, and PK-C activity (14). 
Furthermore, one study with insulin receptors mutated at the ATP-binding 
domain showed that insulin-dependent stimulation of pyruvate 
dehydrogenase bypasses the insulin receptor kinase (23). 
Many genetic studies of patients with various clinical syndromes of 
insulin resistance, including non-insulin-dependent diabetes mellitus 
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(NIDDM), have added evidence that the insulin receptor kinase is involved 
in signal transmission of insulin's actions. A number of studies on 
patients with Type A extreme insulin resistance have shown that insulin 
receptors from these patients have diminished autophosphorylation and 
kinase activity but normal binding in vitro (12,24-28) and are often mutated 
in the tyrosine kinase domain (12,25-28). Studies with these mutant 
receptors in isolated cells have shown that some mutations result in the 
inhibition of insulin-dependent phosphorylation of exogenous substrates 
(pp 185) (12,27), 2-deoxyglucose uptake (28), DNA synthesis (12), or gene 
expression (12). Yet, other mutations have no effect on insulin-stimulated 
2-deoxyglucose uptake and glycogen synthesis (12). Thus, these and the 
above mentioned studies suggest that the insulin receptor kinase is involved 
in transmembrane signaling for many but not all of insulin's actions and 
that a divergence of insulin signaling pathways seems to occur at the level 
of the insulin receptor. 
Many investigators have concentrated on quantitating insulin receptor 
autophosphorylation and kinase activity in an attempt to gain insight into 
the mechanisms responsible for various insulin resistant states, including 
NIDDM. Some studies have concentrated on insulin resistant states 
induced by obesity (13,29,30), fasting (31-33), hyperinsulinemia (34), or 
catecholamines and phorbol esters (17), to examine the effects on insulin 
receptor function, while others have focused on the insulin resistance of 
NIDDM (10,13,30,33,35-51). Researchers have found decreases (10,13,17, 
30,31,34,36,37,39-43,45-50), increases (29,30,33,51), or no change (29,32,35,38, 
44,49) in autophosphorylation (10,13,17,29-33,36,38,39,41-44,46,48,49,51) and 
tyrosine kinase (10,13,17,29-32,34-43,45-51) activities in insulin receptors 
exposed to the above mentioned states of insulin resistance. Tissues from 
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either insulin resistant humans (10,13,36,37,40, 45,47,50) or animals (17, 
29-35,38,39,41-44,46,48,49,51) have been used in the studies. A majority of the 
above studies have shown that decreases in insulin receptor autophospho¬ 
rylation and/or tyrosine kinase activity are present in insulin resistant 
subjects. These observations suggest that a defect(s) at the level of signal 
transmission is responsible for insulin resistance. However, as will be 
discussed below, a number of differences in models and methodology may 
make some studies less physiologically relevant. 
While the transmembrane signaling mechanisms involved in insulin 
action have been studied intensely, only recently have investigations 
focused on the mechanism(s) by which the insulin receptor is deactivated. 
Unlike many other receptors, the insulin receptor tyrosine kinase remains 
active even after insulin dissociates from its binding site (11,52). The kinase 
can be inactivated by phosphorylation of serine residues in the (3-subunit 
(6,11). Phorbol esters and cAMP have been shown to stimulate serine 
phosphorylation of the insulin receptor thus inhibiting the receptor kinase 
(6,11). However, some studies have suggested that this mechanism of 
receptor deactivation may be a mechanism of regulating insulin receptor 
activity by other hormones (i.e. glucagon, catecholamines) rather than a 
mechanism of terminating insulin's signal (6,17). 
Many investigators have concentrated instead on the dephosphorylation 
of autophosphorylation sites by phosphotyrosine protein phosphatases as a 
mechanism of insulin receptor deactivation. A number of phosphotyrosine 
phosphatases have been isolated that have activity against the autophos- 
phorylated insulin receptor or similar phosphorylated peptides (9,52-59), 
and some phosphatases can be stimulated by insulin (58,60,61). In 
addition, other phosphotyrosine phosphatases have been isolated that 
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possess activity against the phosphotyrosine forms of known exogenous 
substrates of the insulin receptor tyrosine kinase such as histones (62,63), 
casein (64,65), and poly Glu/Tyr(4:l) (54,66,67). Yet, no phosphatase activity 
is intrinsic to the insulin receptor (56). Thus, phosphotyrosine phospha¬ 
tases may be involved in terminating insulin signal transduction at 
different levels of the signaling pathway. 
Despite the growing evidence supporting the importance of phospho¬ 
tyrosine phosphatases, only a few studies have addressed their role in the 
hepatic insulin resistance of diabetes. The results of these studies are not 
consistent, with reports of a decrease (55), increase (55), or no change (54) in 
phosphatase activity of microsomal (54,55) or PM (54) preparations from 
diabetic rats. In these studies, phosphatase activity was measured with an 
artificial 32p-labelled substrate which may lack the sensitivity to highly- 
specific phosphatases (e.g. phosphopeptide 1142-1153) (55) or may not be 
representative of protein sequences (e.g. 32p_RCM-lysozyme) (54) of the 
insulin receptor. The role of phosphotyrosine phosphatases in the patho¬ 
genesis of the insulin resistance of diabetes remains to be elucidated. 
Previously, this laboratory has reported that autophosphorylation of the 
hepatic insulin receptor of streptozotocin-diabetic rats (a model of NIDDM 
in humans) was unaltered in partially-purified preparations extracted 
from PM (44). This study was initiated because previous studies (33,43) 
examined hepatic insulin receptor preparations made from microsomal 
membranes which may not be physiologically relevant when considering 
insulin action. Similarly, more recent studies (29,30,35,38,39,41,45,48,49) 
examining insulin receptor autophosphorylation and tyrosine kinase 
activity in diabetes have also used preparations not of PM origin. The 
relevance of these investigations is also questionable, especially because a 
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previous study from this laboratory (68) revealed that the contribution of PM 
is only about 20 percent of the total cellular insulin binding in the hepato- 
cyte. The present work establishes assay conditions and extends the 
previous study (44) by evaluating hepatic insulin receptor kinase activity in 
both PM and microsomal preparations from normal and streptozotocin 
diabetic rats. In addition it describes the presence of copurifying ATPases 
and phosphatase activities in these extracts 
The type of buffer to be used in the study needs to be assessed during the 
evaluation of assay conditions. The majority of the previously mentioned 
studies have used either Tris (33,34,37,45,59,63,66,67) or HEPES (10,17,29,30, 
32,36,39-44,46-53,55-57) as buffers. However, there is some evidence that 
Tris-containing buffers may reduce insulin binding capacity (69,70), but the 
ability of Tris to perturb insulin receptor kinase activity has not been 
previously evaluated. 
Another variable in previous studies that needs to be evaluated is the 
use of cytosine triphosphate (CTP). A number of studies (31,35,36,38,40, 
47,50,71-74) have used CTP as an inhibitor of adenosine triphosphatases 
(ATPases) that may copurify with the insulin receptor and diminish the 
apparent receptor kinase activity by limiting its substrate, ATP. CTP is 
used because it does not compete with ATP at the insulin receptor kinase 
(1) but is a good substrate for a number of broad specificity ATPases isolated 
from hepatocyte membranes (75,76). When the effect of CTP on ATPase 
activity has been evaluated, CTP has been effective in inhibiting ATPases in 
most studies (36,38,50,71,74), but some investigators have found no effect 
(31) or inconsistent effects (47) of CTP on ATPase activity. A 10:1 ratio (or 
greater) of CTP:ATP concentrations should be sufficient for inhibition of 
ATPases (76). Ratios of 10 or 20 are used in the majority of studies 
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(31,36,40,50,71,72). In the present study, 2 mM CTP is used to give a 
[CTP/ATP] ratio of 20:1. 
The use of vanadate in previous studies has not been consistent and 
warrants evaluation in the present study. Vanadate is a potent inhibitor of 
many, but not all, phosphotyrosine phosphatases and ATPases (77,78) that 
may copurify with insulin receptors purified on wheat germ agglutinin 
columns (32,79,80). The majority of studies that have used vanadate and 
evaluated its effect on phosphatase and/or ATPase activities have found it to 
be effective (31,38,49,50,71,74), while others have found no inhibitory effect of 
vanadate (33,36,47,79). Most investigators who have found vanadate to be 
effective have used concentrations of 0.1 to 1.0 mM (31,38,49,50,74) which is 
consistent with the fact that most phosphotyrosine phosphatases that have 
been tested from rat liver are inhibited by 0.1 and 1.0 mM vanadate 
concentrations (52-54,56,59). In the present work, 0.1 and 1.0 mM concen¬ 
trations are chosen to be evaluated. 
The effectiveness of vanadate in inhibiting ATPases/phosphatases also 
requires assessment. This ATPase/phosphatase activity can be detected by 
measurement of 32p.0rthophosphate (32p^) generation during incubations 
of insulin receptor preparations with [y32p] ATP. The molybdate technique 
(81), which has been used in previous studies (38,43,74,82), is being used in 
the present study because it allows the measurement of a large number of 
samples taken from very small sample volumes. The data from the present 
study show the presence of ATPase/phosphatase activity that copurifies 
with the insulin receptor through lectin affinity chromatography. 
In order to fully evaluate the activity of the insulin receptor tyrosine 
kinase in these preparations it is necessary to assess activity when 
substrate (ATP) conditions are not limiting. This evaluation can be 
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accomplished by varying the ATP concentration and doing Lineweaver- 
Burke analysis to determine the maximum velocity (Vmax) and Michaelis 
constant (Km) for the insulin receptor kinase (34). The data reveals that 
microsomal and PM insulin receptors from diabetic rat livers have 
decreased kinase activity compared to control rat hepatic insulin receptors. 
Since the previous study from this laboratory (44) was performed at lower 
ATP concentrations and in the absence of vanadate, the ATPase/ 
phosphatase activity detected in this work may explain the earlier finding of 
normal kinase activity in insulin receptors prepared from PM of diabetic 
rats. The results provide the first evidence that the insulin resistance of 
nonketotic diabetes mellitus is associated with a reduction in insulin 




Reagents. Streptozotocin was a gift from The Upjohn Company 
(Kalamazoo, MI); aprotinin, phenylmethylsulfonyl fluoride, poly Glu/Tyr 
(4:1), bovine serum albumin (fraction V), sodium orthovanadate, and 
unlabelled nucleotides were obtained from Sigma (St. Louis, MO); wheat- 
germ agglutinin-agarose (WGA) was from E-Y Laboratories (San Mateo, 
CA); crystalline porcine insulin was a gift from Eli Lilly and Company 
(Indianapolis, IN); [y32p]ATP (3000 Ci/mmol) was obtained from 
Amersham Corporation (Chicago, IL); carrier-free [125j]Na was from New 
England Nuclear (Boston, MA); Dextran T-500 was from Pharmacia-LKB 
(Piscataway, NJ). All other chemicals were reagent grade. 
Animals. Male-Sprague Dawley rats, approximately 2 months old and fed 
ad libitum were used for all studies. Non-ketotic diabetes was induced by 
the injection of streptozotocin (85mg/kg) via femoral vein as described 
previously (83). Rats were used 2 to 4 weeks after injection and had elevated 
serum glucose (>450 mg/dl) and low serum insulin (<8 |iU/ml). 
PM Isolation and Lectin-Purification of the Hepatic Insulin Receptor. 
Purified PM were isolated from 20 g of rat liver from normal and diabetic 
rats as previously described (44,68). Marker enzyme profiles of these 
preparations have been previously reported (68). PM were extracted by 
2-phase polymer method as previously described (68,84). Aqueous polymer 
phases were prepared by mixing 30%(w/w) Polyethylene Glycol-6000 (PEG) 
in H2O with 20%(w/w) Dextran-500 in H2O and 0.22 M phosphate buffer (pH 
6.5), allowing to stand at 4°C for 48 hours, and then collecting the top and 

15 
bottom phases separately. Liver homogenization was performed at 4°C in 
the presence of 1 mM phenylmethylsulfonyl fluoride and 1.0 TIU/ml 
aprotinin. The homogenate was centrifuged at 1200xg for 30 minutes, and 
the pellet was saved and washed with 2 additional lOOOxg centrifugations 
for 15 minutes each. The pellets were saved, suspended in top and bottom 
phases, and centrifuged in a swinging bucket rotor at llOOxg for 15 
minutes. PM were removed from the interface between the polymer phases 
using a pasteur pipet, resuspended in top and bottom phases, and 
centrifuged at llOOxg for 15 minutes. This collection and separation of PM 
was repeated once more with the polymers, and then PM were washed in 50 
mM Tris (pH 7.5) to dispel the polymers and spun at 2400xg for 10 minutes. 
This Tris wash was repeated once, and then the pellets were then 
resuspended in HEPES buffer, homogenized and stored at -70°C. PM 
insulin receptors were extracted as previously described (68,84) except that 
the final Triton X-100 concentration was increased from 1 to 2%(v/v). After 
clarification of the detergent extract by centrifugation at 100,000xg for 60 
minutes, the supernatant was diluted to 0.5%(v/v) Triton X-100 and recycled 
three times through a WGA affinity column (44). After washing the 
column with 50 mM HEPES buffer, pH 7.6, containing 150 mM NaCl, 10 
mM MgS04, 0.02%(w/v) sodium azide, and 0.1%(v/v) Triton X-100, elution of 
the insulin receptor was achieved by the inclusion of 300 mM N-acetyl-D- 
glucosamine in the above buffer. The protein content of column eluates was 
determined by the dye-binding (Coomassie Blue) method of Bradford (85) 
(Bio Rad Protein Assay) using bovine gamma globulin as the standard. 
Aliquots were frozen at -70°C. The protein concentration of pooled fractions 
was generally 0.8 to 1.4 mg/ml. 
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Preparation of Microsomes. Microsomal membrane preparations were 
prepared at 4°C from 20 grams of liver following homogenization in 50 mM 
HEPES buffer, pH 7.6, containing 250 mM sucrose, 1 mM phenylmethyl- 
sulfonyl fluoride and 1 TIU/ml aprotinin. The homogenate was centrifuged 
at 10,000xg for 20 minutes, the supernatant removed, and centrifuged at 
100,000xg for 60 minutes. The pellet (microsomes) was saved, washed with 
an additional 100,000xg centrifugation, and partially-purified on WGA 
columns following solubilization in Triton X-100 as described above. 
Insulin Binding ofWGA-Column Eluates. 125j_insuiin was prepared by 
the Chloramine-T method as described by Cuatrecases (82). Prior to use, 
the iodinated insulin was purified on a Bio-Gel P-30 column. Aliquots (5 to 
15 pg of protein) of WGA column eluates were incubated with 125j_insuiin 
(1 nM) in the presence and absence of 1 pM unlabelled insulin for 15 to 120 
minutes at 24°C in phosphorylation buffer (see below), unless otherwise 
noted. The incubation was terminated by placing on ice and adding bovine 
gamma globulin and 10% PEG as previously described (68). Samples were 
then centrifuged for 1 minute in a Beckman microfuge at 10,000xg. Pellets 
were then washed with 10% PEG and counted in a gamma-counter. 
Samples were run in quadruplicate, and data expressed in fmol insulin 
bound/mg protein + standard deviation. For kinase and other assays, equal 
binding for diabetic and control preparations was determined by varying 
receptor protein concentrations at the same time of incubation, and then 
the appropriate preparation was diluted with phosphorylation buffer. 
Preliminary studies established that recovery of receptors with WGA 




Insulin Receptor Tyrosine Kinase Activity. Aliquots of lectin-purified PM 
and microsomal insulin receptor preparations containing equal binding 
activity (bound/total ranged from 10 to 15%) from normal and diabetic rats 
were incubated at 24°C for 90 to 120 minutes in the absence and presence of 
100 nM insulin in a buffer solution (total volume of 30 |il) modified from Zick 
et al. (82). Except where noted, the phosphorylation buffer consisted of 50 
mM HEPES buffer, pH 7.6, 50 mM NaCl, 20 raM MgCl2, 2 mM 
Mn(CH3COO')2, 0.02%(w/v) bovine serum albumin, and 0.1%(v/v) Triton X- 
100. Phosphorylation was initiated by the addition of a 10 pi solution 
containing [y32p]ATP (final concentration 100 |iM), sodium orthovanadate 
(final concentration 0, 0.1, or 1 mM), p-nitro-phenylphosphate (pNPP) (final 
concentration 0 or 10 mM), and CTP (final concentration 0 or 2 mM). After 
a 10 minute incubation at 24°C, 10 pi of phosphorylation buffer containing 
poly Glu/Tyr (4:1) (final concentration was 1 mg/ml) were added (total 
volume of 50 pi), and the incubation continued for an additional 5 to 20 
minutes. The reaction was terminated with one-half volume of a "stopping 
solution" (82) consisting of 50 mM HEPES buffer, pH 7.4, 40 mM NaH2P04, 
20 mM EDTA-Na, 200 mM NaF, 40 mM sodium pyrophosphate, 40 mM 
ATP, 20 mM pNPP, 5 mM sodium orthovanadate, and 0.4% Triton. 
Aliquots were precipitated with tricholoracetic acid on Whatman 3MM 
filter papers as described by Zick et al. (72). Filter papers were dried then 
placed in cold 10% trichloroacetic acid (TCA) for 90 minutes. Filter papers 
were then rinsed, and cold 10% TCA was replaced for 60 minutes. A third 
10% TCA rinse of 15 minutes was performed, and then filter papers were 
washed in 95% ETCH for 10 minutes. Filter papers were rinsed with 
diethylether (reagent), dried, and then counted by liquid scintillation. 
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Insulin dose response for tyrosine kinase activity was assessed by the above 
procedure, but the insulin concentration was varied from 0 to 10"^ M. 
Background subtractions were made by determining radioactivity on filters 
prepared from incubations performed in the absence of insulin receptor 
and/or poly Glu/Tyr(4:l). Kinase activity was expressed in pmol 32p 
incorporated/fmol insulin-binding over 10 minutes of kinase incubation. 
Samples were run in triplicate or quadruplicate. 
Evaluation of Trichloroacetic Acid Wash Procedure. The TCA wash 
procedure was used to precipitate the 32p_Giu.rpyr(4:i)j as described above. 
The efficiency of the washes was evaluated in the following manner. 
Control microsomal insulin receptors were incubated with [y32p]ATP for 10 
minutes and then quenched with the "stopping solution" as described 
above. Aliquots were spotted on filter papers and placed in 10% TCA. To 
assess the stickiness of [y32p]ATP, blank filter papers were also placed in 
the TCA. In wash procedure #1 washes were 90 minutes and then three 60 
minute washes, while in wash procedure #2 washes were 90 minutes and 
then three 15 minutes washes. Blank and sample filter papers were 
withdrawn (in quadruplicate) and counted after each TCA wash. Data was 
expressed as pmol 32p 0n filter paper/fmol of insulin bound. 
Determination of Orthophosphate. 32p_orthophosphate content was 
determined by the molybdate technique as described by Reinmann and 
Umfleet (81). Aliquots from incubations were applied to Whatman 3MM 
filter papers which were then placed in molybdate solution consisting of 
1.5% TCA, 0.74% ammonium molybdate, and 7.4 mM triethylamine. Filter 
papers were swirled occasionally for 10 minutes. Molybdate solution was 
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then used to wash the filter papers for four more 10 minute periods. Filter 
papers dried overnight and then were counted in a beta counter. Data was 
expressed as either percent hydrolysis or pmol 32p_orthophosphate 
formed/fmol insulin binding over 20 minutes of hydrolysis. Samples were 
run in quadruplicate. 
Lineiveaver-Burke Analysis. Insulin receptor tyrosine kinase activity was 
assayed as discussed above except that the concentration of [y32p]ATP was 
varied from 25 pM to 400 |iM. Data was expressed as above but was plotted 
as a double reciprocal graph to allow Lineweaver-Burke analysis as 
described in (29). Linear regression was performed in order to determine 
maximum velocity (Vmax) and Michaelis constant (Km) for each set of 
data. 
Statistics. Statistical analyses were performed by using the non-paired 
two-tailed Student's t Test. 
Disclaimer. I performed all of the above methods with the exceptions of the 
preparation of 125i_insuijn by the Chloramine-T method and the 




Insulin Binding ofWGA-Column Eluates. Partially-purified insulin 
receptors from PM and microsomes isolated from control and 
streptozotocin-diabetic rats were evaluated for insulin binding (tracer). 
As shown in Figure 1, insulin binding to hepatic microsomal insulin 
receptors from control and diabetic rats approached equilibrium between 
60 and 90 minutes at 24°C which is similar to the results of other studies 
performed at the same temperature (42,43,46). As reported by others 
(30,39,41,43, 48,49), insulin binding was found to be higher (55-89%, 481±85 
and 747+66 fmol insulin bound/mg protein for normal and diabetic prepara¬ 
tions respectively at 120 minutes incubation, p<0.05) (mean + standard 
deviation) in WGA extracts from diabetic rat livers (Figure 1). This result 
was in contrast with one study (35) which found decreased (by 50%) insulin 
binding in alloxan-diabetic rat preparations. Previous studies (35,39,49) 
have shown that these diabetes-induced changes in insulin binding are due 
to alterations in receptor number and not receptor affinity. 
Insulin binding in PM insulin receptors from control and diabetic 
rats approached equilibrium in 60 to 90 minutes (Figure 2). This 
equilibrium time was similar to that observed with microsomal prepara¬ 
tions at 24°C (Figure 1). Consistent with previous studies (38,44,45,51,68) 
but in contrast to the results with microsomes, no difference in insulin 
binding activity was found between control and diabetic PM insulin receptor 
preparations, (261+104 and 285+118 fmol insulin bound/mg protein for 
normal and diabetic preparations, respectively) (Figure 2). A previous 
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Figure 1. 1251-INSULIN BINDING IN HEPATIC 
MICROSOMAL INSULIN RECEPTORS 
* 
Figure 2. 125 I-INSULIN BINDING IN HEPATIC 
PM INSULIN RECEPTORS 
125 
Figures 1.2. I-insulin binding in hepatic insulin receptors. 
Aliquots of lectin-purified hepatic microsomal (Figure 1) and 
PM (Figure 2) insulin receptors from normal (open circles) and 
diabetic (solid circles) rats were incubated with125I-insulin 
(InM) in the presence and absence of unlabelled insulin ( }iM) 
for 15 to 120 minutes in phosphorylation buffer as described in 
Methods. The data represent the mean values from two to 
four experiments each performed in quadruplicate. Statistical 
comparisons between control and diabetic groups. * p<0.05. 
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study (68) has also shown no difference in insulin binding affinity between 
control and diabetic PM insulin receptors. 
Evaluation of Trichloroacetic Acid Wash Procedure. Figure 3 shows that 
the effectiveness of the washing of filter papers with TCA seemed to be more 
dependent on the number of washes rather than on the duration of each 
wash. Radioactivity on the filter papers with receptors reached a near 
steady-state by the third wash of each wash procedure (Figure 3). 
Presoaking the filter papers as described by Zick et al. (72) had no effect on 
results (data not shown). Blank filter papers showed that the degree of 
[y32p]ATP "stickiness" had also diminshed to a steady state by the third 
wash and was a small percentage of the microsomal receptor activity (14- 
18%) (Figure 3). For all subsequent experiments, a wash procedure of 90, 
60, and 15 minute washes was employed. 
Determination of Incubation Conditions for Insulin-Stimulated 
Tyrosine Kinase Assay. The effects of pNPP and vanadate on both insulin 
binding and tyrosine kinase activity were assessed in control and diabetic 
microsomal preparations initially equalized for binding in buffer lacking 
these agents. As shown in Figure 4, pNPP (10 mM) and vanadate (0.1 and 
1.0 mM) decreased insulin binding in microsomal insulin receptors by 20 to 
29%. The relationship of insulin binding between diabetic and control 
persisted in all three conditions. Because of this decrement in insulin 
binding with pNPP and vanadate, later experiments involving these 
inhibitors were conducted so that these inhibitors were added only with and 
























































Figure 3. EVALUATION OF TCA WASH PROCEDURE 
Figure 3. Evaluation of trichloroacetic acid wash procedure. 
As described in Methods, filter paper discs contained radio¬ 
activity from microsomal insulin receptors incubated with 
32 
[y P]ATP (solid circles and triangles) or from blank discs 
(open circles and triangles). Discs were washed with four 
successive washes according to procedure #1 (90 minutes then 
60, 60, 60 minutes: circles) or procedure #2 (90 minutes then 15, 
15, 15 minutes: triangles). Discs were removed in quadruplicate 
after each wash and counted. The data represent mean values 
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EFFECT OF pNPP AND VANADATE 
ON INSULIN BINDING 
CONTROL DIABETIC 
Figure 4. Effect of pNPP and vanadate on insulin binding. 
Aliquots of hepatic microsomal insulin receptors equalized 
125 
for binding were incubated in I-insulin in the absence 
and presence of phosphorylation buffer containing 10 mM 
pNPP and 0.1 and 1.0 mM vanadate. (B=kinase buffer 
without inhibitors; PV-L, PV-H=kinase buffer with 10 mM 
pNPP and 0.1 or 1.0 mM vanadate, respectively.) Data 




Preliminary experiments without pNPP or vanadate showed 
minimal insulin-stimulated tyrosine kinase activity and a high degree of 
variability in both microsomal and PM preps. As shown in Figure 5 
(incubation time with poly Glu/Tyr[4:l]=10 minutes), the addition of pNPP 
(10 mM) and vanadate (0.1 [PV-L] or 1.0 mM [PV-H]) to microsomal 
preparations enhanced insulin-stimulated tyrosine kinase activity in the 
control group (from 1.35+1.40 to 3.49±0.80 {+159%} or 3.60+1.14 {+167%} with 
PV-L or PV-H, respectively pmol 32p incorporated/fmol insulin binding) 
and in the diabetic group (from 1.73+0.91 to 2.02+0.30 {+17%} or 2.86+0.85 
{+65%} with the addition of PV-L or PV-H, respectively). The relationship 
between control and diabetic groups from microsomes was also altered with 
the addition of vanadate and pNPP. Without inhibitors the diabetic kinase 
activity was greater than the control (% Diabetic/Control [%D/C]= +28%), 
whereas with inhibitors the opposite was true [%D/C= -42% (PV-L), -21% 
(PV-H)]. 
As shown in Figure 6 (incubation time with poly Glu/Tyr[4:l]=10 
minutes), the addition of pNPP and vanadate to PM insulin receptor 
preparations enhanced insulin-stimulated tyrosine kinase activity. In the 
control group, kinase activity increased from .09+.07 to 1.26+.56 or 1.45+.76 
with PV-L or PV-H, respectively (pmol 32p incorpo- rated/fmol insulin 
binding). Similarly, in the diabetic group kinase activity increased from 
.01+.01 to 1.84+.88 or 1.63+.84 with PV-L or PV-H, respectively (same units 
as above). The effect of pNPP and vanadate on the variability of the data 
was hard to assess because of the very low kinase activity without 
inhibitors. The large increase in kinase activity with vanadate suggested a 
high degree of contamination with ATPases/ phosphatases. The 


















EFFECT OF pNPP AND VANADATE ON 
INSULIN-STIMULATED TYROSINE KINASE 
ACTIVITY IN MICROSOMES 
CONTROL DIABETIC 
Figure 6. EFFECT OF pNPP AND VANADATE ON 
INSULIN-STIMULATED TYROSINE KINASE 
ACTIVITY IN PM 
< J 
> 3 







Figures 5.6. Effect of pNPP and vanadate on insulin stimulated tyrosine 
kinase activity (AI) in microsomal (Figure 5) and PM (Figure 6) prepara¬ 
tions. Aliquots of lectin-purified hepatic microsomal and PM insulin 
receptors from normal and diabetic rats were incubated in the presence 
of 100 nM insulin, 100|JV1 [y 32 P]ATP, and phosphorylation buffer with 
varying concentrations of pNPP and vanadate. (B=phosphorylation 
buffer without inhibitors; PV-L, PV-H= kinase buffer with 10 mM pNPP 
and 0.1 or 1.0 mM vanadate, respectively). Data represents mean values 
two to four experiments performed in quadruplicate. Insulin-stimulated 
tyrosine kinase activity (AI) was defined as kinase activity with insulin 
minus kinase activity without insulin. Incubation time with poly 
Glu/Tyr(4:l) was 10 minutes. 
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altered with the addition of pNPP and vanadate. Without inhibitors both 
diabetic and control insulin receptors exhibited very little insulin- 
stimulated kinase activity, but the control had slightly more kinase activity 
than the diabetic prep. With inhibitors the diabetic kinase activity was 
greater than the control [%D/C= 1.84+.88/1.26+.56= +46%(PV-L); %D/C= 
1.63±.84/1.45±.76= +12%(PV-H)], but there was a high degree of variability 
which precluded statistical comparisons. These increases in kinase 
activity in diabetic PM is in contrast to the previous study by this laboratory 
(44) in which insulin-sensitive insulin receptor autophosphory- lation was 
unchanged in the diabetic, but in the PV-H group the diabetic and control 
kinase activities were more similar than in the PV-L group. 
The effect of Tris buffer on insulin-stimulated tyrosine kinase activity 
in microsomal insulin receptors was measured in the presence of 0.1 mM 
vanadate and 10 mM pNPP (incubation time with poly Glu/Tyr[4:l]=10 
minutes). An initial experiment established insulin binding to be identical 
when comparing activity in HEPES or Tris and to have no effect in the 
insulin binding relationship of control and diabetic microsomal prepa¬ 
rations (data not shown). As shown in Table 1, Tris buffer reduced tyrosine 
kinase activity in the control preparation by 36% (7.94 and 5.08 pmol 32p 
incorporated/fmol insulin binding for HEPES and Tris buffers, respectively) 
but had little effect on kinase activity in the diabetic preparation (4.00 and 
4.13 for HEPES and Tris buffers, respectively in same units as above). The 
relationship of less kinase activity in the diabetic preparation remained 
intact although Tris decreased this difference. Because Tris buffer 
selectively reduced insulin receptor kinase activity in the control 
preparation, all subsequent experiments were conducted in HEPES buffer. 

Table 1. Effects of Tris and HEPES Buffers on 
Insulin-Stimulated Tyrosine Kinase Activity 
in Microsomes 
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Tyrosine Kinase Activity (AI) 
(pmol 32 P incorp/fmol insulin bound.) 
BUFFER CONTROL DIABETIC ft. D/C 
Hepes 7.94 4.00 -50% 
Tris 5.08 4.13 -19% 
% change 
due to Tris 
-36% +3% 
Table 1. Effects of Tris and HEPES buffers on insulin-stimulated tyrosine 
kinase activity in microsomes. Aliquots of lectin-purified hepatic micro¬ 
somal insulin receptors from control and diabetic rats were incubated in 
the presence of 100 nM insulin, poly Glu/Tyr(4:l)(incubation time=10 
minutes), 100 pM ATP, 10 mM pNPP, 0.1 mM vanadate, and phosphorylation 
buffer made with either Tris or HEPES. The data represent the mean 
values from one experiment performed in quadruplicate. 
Table 2. Effect of CTP on Insulin-Stimulated 
Tyrosine Kinase Activity in Microsomes 
Tyrosine Kinase Activity (AI) 
(pmol 32 P incorp/fmol insulin bound). 
CTP CONTROL DIABETIC %D/C 
0 mM 3.12 1.75 44% 
2 mM 0.89 0.55 -38% 
% change -71% -69% 
due to CTP 
Table 2. Effect of CTP on insulin-stimulated tyrosine kinase activity in 
microsomes. Aliquots of lectin-purified hepatic microsomal insulin 
receptors from control and diabetic rats were incubated in the presence of 
100 nM insulin, poly Glu/Tyr(4:l)(incubation time=10 minutes), IOQjM ATP, 
10 mM pNPP, 0.1 mM vanadate, and CTP (0 or 2 mM). The data represent 
the mean values from one experiment performed in quadruplicate. 
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The effect of CTP on insulin-stimulated tyrosine kinase activity was 
investigated using hepatic microsomal insulin receptors isolated from 
control and diabetic rats. Insulin receptors were incubated in the presence 
of 0.1 mM vanadate and 10 mM pNPP (incubation time with poly 
Glu/Tyr[4:l]=10 minutes). Table 2 shows that the addition of CTP (2mM) 
resulted in a similar decrease (ca. 70%) in insulin-stimulated kinase 
activity in the control and diabetic preparations. This result is in contrast 
to previous studies in which CTP enhanced insulin receptor tyrosine kinase 
activity (36,38,50,71,74) or had no effect on tyrosine kinase activity (31). 
Although the relationship between diabetic and control kinase activities 
(%D/C= -44%) was preserved in the presence of CTP (%B/C with CTP= - 
38%), CTP was omitted in subsequent experiments because of the negative 
influence on both diabetic and control receptor activities. 
Evaluation of the Time Course of Insulin Receptor Tyrosine 
Kinase Activation. Experiments were performed in the absence or 
presence of 1.0 mM vanadate and 10 mM pNPP (PV-H). Incubation time 
with poly Glu/Tyr(4:l) was varied from 5 to 20 minutes in order to evaluate 
the time course of microsomal and PM insulin receptor kinase activity 
isolated from control and diabetic rats. In microsomal hepatic insulin 
receptors without vanadate and pNPP, the control group kinase activity 
approaches equilibrium (5-10 minutes) before the diabetic group kinase 
activity (10-20 minutes) (Figure 7). However, when vanadate and pNPP 
were added to the reaction mixture, activation of both control and diabetic 
receptor kinases was nearly linear for up to 20 minutes. All other 
experiments with microsomes were incubated with poly Glu/Tyr(4:l) for 10 
minutes in order to make linear measurements of tyrosine kinase activity. 
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Figure 7. TIME COURSE OF INSULIN RECEPTOR 




























Figure 7. Time course of insulin-stimulated tyrosine kinase activity 
in microsomal preparations. Aliquots of lectin-purified hepatic 
microsomal insulin receptors from normal (open circles and triangles) 
and diabetic (solid circles and triangles) rats were incubated in the 
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presence of 100 nM insulin, 100 |M [7 P]ATP, and phosphorylation 
buffer without (circles) or with (triangles) pNPP (10 mM) and vanadate 
(1 mM). Incubation time with poly Glu/Tyr(4:l) was varied from 5 to 20 




This incubation time was shorter in comparison to those used in previous 
studies conducted at 24°C (31,34,37,38,46). In one study conducted without 
vanadate, incubation time was 20 minutes (34), but those studies done in the 
presence of vanadate used incubations of 15 to 30 minutes (31,37,38,46). 
Interestingly, one study (30) that was conducted at 4°C with vanadate 
showed that microsomal insulin receptor tyrosine kinase activity was 
linear with respect to time for up to 120 minutes. 
Diabetic microsomal receptor kinase activity was less than control 
activity at all time points to a similar degree (%D/C= -16% to -40%) when 
incubated with vanadate and pNPP. In their absence, control kinase 
activity was greater than diabetic activity at 5 minutes but had become less 
than diabetic activity at 20 minutes. These results thus suggest the 
presence of a greater degree of ATPase/phosphatase activity (causing [ATP] 
to become more limiting with time) in the control preparation. 
In PM, the time course of insulin receptor tyrosine kinase activation 
could only be assessed in the presence of vanadate and pNPP because poor 
insulin responses were observed without inhibitors. As shown in Figure 8, 
kinase activation in both control and diabetic insulin receptors remained 
nearly linear with respect to time through 10 minutes of incubation. 
However, by 20 minutes both control and diabetic activities had plateaued. 
The former plateaued sooner and at a lower kinase activity which 
suggested that [ATP] was becoming limiting or dephosphorylation was 
occurring and to a larger degree in the control preparation. Consequently, 
an incubation time of 10 minutes was chosen for all other experiments with 
PM. 
Evaluation of the Effect of Insulin Concentration on Insulin 
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Figure 8. TIME COURSE OF INSULIN RECEPTOR 
TYROSINE KINASE ACTIVATION IN PM 
3 5 












Figure 8. Time course of insulin-stimulated tyrosine kinase 
activity in PM preparations. Aliquots of lectin-purified 
hepatic PM insulin receptors from normal (open circles) and 
diabetic (solid circles) rats were incubated in the presence of 
32 
100 nM insulin, 100 [y P]ATP, and phosphorylation 
buffer with pNPP (10 mM) and vanadate (1 mM). Incubation 
time with poly Glu/Tyr(4:l) was varied from 5 to 20 minutes. 
Data represent the mean values from two experiments 
performed in quadruplicate. 
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Receptor Tyrosine Kinase Activity. The effect of insulin concentration on 
tyrosine kinase activity was evaluated in both microsomal and PM insulin 
receptors in the presence of 0.1 mM vanadate and 10 mM pNPP as 
described in Methods. As shown in Figures 9 and 10, microsomal and PM 
insulin receptor kinases were activated at both physiologic (0.1 and 1.0 nM) 
and pharmacologic (10 and 100 nM) insulin concentrations. Physiologic 
and pharmacologic concentrations of insulin have previously been shown to 
stimulate the insulin receptor tyrosine kinase in intact hepatocytes (80). 
Figure 9 shows that the dose response curves for control and diabetic 
microsomal receptor kinase activities were almost identical in shape. 
Diabetic and control kinase activities were similar at all insulin 
concentrations in this preparation. 
As shown in Figure 10, the dose response curves for control and 
diabetic PM receptor kinase activities were similar in shape. However, for 
this particular preparation, the diabetic receptor kinase activity was 
greater than the control receptor kinase activity at all concentrations of 
insulin tested (%D/C= +36 to +64% for [insulin] > 1.0 nM). 
32p-Orthophosphate Formation in Insulin Receptor Preparations. 
In view of studies demonstrating changes in the membrane concentration 
of ion-pump ATPases in diabetes (88,89), the extent of 32p-0rthophosphate 
generation was measured concomittant with measurements of poly 
Glu/Tyr(4:l) phosphorylation, as described above. The results of these 
experiments with microsomal and PM preparations are shown in Figures 
11 and 12, respectively. In the absence of vanadate and pNPP, the amount 















EFFECT OF [INSULIN] ON INSULIN RECEPTOR 













Figure 10. EFFECT OF [INSULIN] ON INSULIN RECEPTOR 
TYROSINE KINASE ACTIVITY IN PM 
Figures 9.10. Effect of insulin concentration on insulin receptor 
tyrosine kinase activity in microsomal (Figure 9) and PM (Figure 10) 
preparations. As described in Methods, aliquots of lectin-purified 
hepatic microsomal and PM insulin receptors from normal (open 
circles) and diabetic (solid circles) rats were incubated in the presence 
of [y 32 P]ATP (100 |jM), pNPP (10 mM), vanadate (O.lmM), and varying 
concentrations of insulin (0 to 100 nM). Basal tyrosine kinase activity 
in microsomes was 0.76 (control) and 0.81 (diabetic) (pmol32 P 
incorporated/fmol insulin bound), while it was 0.99 in control and 
1.05 in diabetic from PM preparations. Data represent the mean 
values from one (microsomal) or four replicate (PM) experiments 
performed in quadruplicate. 
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was 74 (9.0% hydrolysis) and 45 (5.1% hydrolysis) in insulin receptor 
preparations from microsomes of normal and diabetic rats, respectively 
(Figure 11) and was 313 (23% hydrolysis) and 247 (18% hydrolysis) in insulin 
receptor preparations from PM of normal and diabetic rats, respectively 
(Figure 12). In the presence of the vanadate and pNPP, an 88% decrease in 
32p-orthophosphate levels was found in control microsomal insulin 
receptor preparations (Figure 11: decreased to 8.9 [1.1% hydrolysis]), while 
an 87% decrease was seen in diabetic microsomal insulin receptor prepa¬ 
rations (Figure 11: decreased to 5.8% [0.7% hydrolysis]). In contrast, the 
addition of vanadate to insulin receptor preparations from PM resulted in 
decreases of only 41% in preparations from normal (Figure 12: decreased to 
185 [14% hydrolysis]) and 61% in preparations from diabetic (Figure 12: 
decreased to 96 [7.1% hydrolysis]) rats. 
The generation of 32p.orthophosphate was less in the diabetic 
preparation than in the control preparation for each set of experimental 
conditions. In the microsomal insulin receptor preparations, the level of 
32p-orthophosphate formation was 39% or 35% less in the diabetic group 
than in the control group when incubated in the absence or presence of 
vanadate and pNPP, respectively. Similarly, in the PM insulin receptor 
preparations, the diabetic group exhibited 21% less 32p_0rthophosphate 
formation than the control group in the absence of vanadate and 48% less 
than the control group in the presence of vanadate. 
These results suggested that ATPase and/or phosphatase activity 
was present in all preparations of insulin receptors tested. This activity 
was 4 to 21 times greater at all experimental conditions in preparations of 
PM origin than in preparations from microsomes. Furthermore, vanadate 





32P-ORTHOPHOSPHATE FORMATION IN INSULIN 























32 P-ORTHOPHOSPHATE FORMATION IN INSULIN 
RECEPTOR PREPARATIONS FROM PM 
31 and pNPP and pNPP 
CONTROL DIABETIC 
Figures 11.12. P-orthophosphate formation in insulin receptor 
preparations. Aliquots of lectin-purified hepatic microsomal (Figure 
11) and PM (Figure 12) insulin receptors from control and diabetic 
rats were incubated in the presence of 100 jjM [y32 P]ATP, 100 nM 
insulin, poly Glu/Tyr(4:l), and kinase buffer without (B) or with pNPP 
(10 mM) and vanadate^l mM). Samples from aliquots were sub¬ 
sequently assayed for z P-orthophosphate content as described in 
Methods (20 minutes of hydrolysis). Data represent the mean values 
from two experiments performed in quadruplicate. 
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insulin receptor preparations from microsomes than in those from PM. 
These ATPases and/or phosphatases were also found to be less active in 
comparable preparations from diabetic rats than those from normal rats. 
Determination of the Effect of ATP Concentration on Insulin Receptor 
Tyrosine Kinase Activity. In order to assess the activity of the insulin 
receptor tyrosine kinase without the confounding factor of copurifying 
ATPase/phosphatase activity, tyrosine kinase activity was evaluated when 
at multiple ATP concentrations. These experiments were conducted by 
varying the ATP concentrations (25 to 400 pM) and using double reciprocal 
plots (Lineweaver-Burke) for analysis of tyrosine kinase activity in order to 
determine the Vmax and Km for the insulin receptor kinase from normal 
and diabetic preparations in the presence of 1 mM vanadate and 10 mM 
pNPP as described above. As shown in Figures 13 and 14, the Vmax was 
reduced by 42% in the diabetic preparation from microsomes (Figure 13: 
6.80 and 3.97 pmol 32p incorporated/fmol insulin binding for control and 
diabetic preparations, respectively) and by 43% in the diabetic group from 
PM (Figure 14: 6.37 and 3.64 pmol 32p incorporated/fmol insulin binding 
for control and diabetic preparations, respectively). The relationship of 
greater kinase activity in the control group remains intact at all ATP 
concentrations tested in microsomal preparations, but in PM preparations 
this relationship inverts at ATP concentrations less than about 150 pM. 
These ATPase/phosphatase activities were also consistent with an 
observed diabetic Km (Figure 14: 45 pM ATP) which is 76% less than the 
control Km (Figure 14: 190 pM ATP) in PM preparations. Higher ATPase/ 
phosphatase activity in the control group would increase the Km- In 
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Figures 13.14. The effect of ATP concentration on insulin receptor 
tyrosine kinase activity in PM and microsome preparations. 
Aliquots of lectin-purified hepatic PM and microsomal insulin 
receptors from control (open circles) and diabetic (solid circles) 
rats were incubated in the presence of 100 nM insulin, 25 to 400 pM 
[y 32p]ATP, and poly Glu/Tyr(4:l) as described in Methods. The 
data are expressed in double reciprocal plots and represent the 
mean values from one experiment performed in quadruplicate. 
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the diabetic Km was still 35% less than the control (Figure 14: 36 and 55 pM 
ATP in diabetic and control preparations, respectively). These results are 
consistent with previous studies in which the Km of ATP for the insulin 
receptor tyrosine kinase was found to range from 30 to 150 pM ATP 




A major interest of this laboratory has been to explore the 
mechanisms underlying hepatic insulin resistance. With regard to the 
insulin resistance of nonketotic diabetes mellitus, this laboratory has 
previously reported (44) that PM insulin receptor autophosphorylation in 
response to insulin was normal in streptozotocin-induced diabetic rat 
livers. It was concluded that the hepatic insulin resistance of nonketotic 
diabetes mellitus resides distal to insulin receptor binding and autophos¬ 
phorylation. The present study extended the earlier work by this laboratory 
(44) by examining the tyrosine kinase activity (toward poly Glu/Tyr[4:l]) of 
hepatic insulin receptors prepared from the PM of normal and strep- 
tozotocin-diabetic rats. For comparison, insulin receptors were prepared 
from hepatic microsomes and were analyzed. 
Experiments testing insulin binding were conducted in order to 
equalize binding between control and diabetic insulin receptor preparations 
and to confirm previous observations of insulin binding in microsomes and 
PM. The finding of increased binding in microsomal insulin receptors 
isolated from diabetic rats (Figure 1) was consistent with the results of 
earlier studies (30,39,41,43 48,49). In contrast, one study using a different 
rat model of diabetes did find reduced insulin binding in diabetic micro¬ 
somal receptors (35). Experiments with PM preparations (Figure 2) 
revealed no difference in insulin binding activity between control and 
diabetic receptors and confirmed the observations made by this laboratory 
(44) and other investigators (38,45,51,68). It is unclear why microsomal 
insulin binding increases in diabetes while PM insulin binding remains 
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unchanged. Perhaps insulin receptor degradation decreases in diabetes 
leading to receptor accumulation in the microsomal compartment. 
Experiments were performed to evaluate the effect of insulin 
concentration on insulin receptor tyrosine kinase activity (Figures 9,10). 
Because receptor kinase activity was enhanced at all insulin concentrations 
tested (0.1 to 100 nM), results from the present study that were obtained 
using 100 nM insulin were the result of a true insulin effect rather than the 
early stage of a growth factor effect which occurs at insulin concentrations 
of greater than 1000 nM (6). 
Initial experiments measuring tyrosine kinase activity revealed a 
high degree of variability. The trichloroacetic acid wash procedure was 
evaluated in order to eliminate the washing of filter papers as a possible 
source of this variability. TCA washing was found to be quite effective in 
bringing radioactivity on filter papers to a steady state within three washes 
while minimizing the degree of [y32p]ATP "stickiness" (Figure 3). Thus, it 
is unlikely that inefficient TCA washing of filter papers accounted for the 
variability seen in the tyrosine kinase assay. 
In addition to the variability observed in the assay, insulin- 
stimulated tyrosine kinase activity in PM receptors was minimal in initial 
experiments. The type of buffer was investigated as a possible source of this 
blunting of kinase activity. Tris buffer had no direct effect on insulin 
binding but did seem to inhibit kinase activity in microsomal insulin 
receptors (Table 1). So, in addition to Tris affecting insulin receptor 
recycling in intact cells (69,70), the current results show a direct inhibitory 
effect on insulin receptor tyrosine kinase activity. The mechanism 
underlying this inhibitory effect of Tris is unclear at the present time. 
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Just as initial tyrosine kinase results were variable in the present 
study, the literature is filled with inconsistencies with regard to hepatic 
insulin receptor tyrosine kinase measurements. Previous investigations 
examining hepatic insulin receptor tyrosine kinase in diabetes have pointed 
towards alterations, but the results have been contradictory (29,30,33,35,38, 
39,41,43-45,48,49). If the methodologies used in these studies are compared, 
one observes that in all (30,39,45,48,49) but one study (44) receptor tyrosine 
kinase activity was reduced in the diabetic groups when insulin receptor 
preparations were incubated with [y32p]ATP at 4°C. In contrast, when 
insulin receptor preparations were incubated at ambient temperatures (20- 
24°C) and in the absence of vanadate, a majority of studies (29,35,49) 
demonstrated no change or even enhanced receptor tyrosine kinase activity 
in diabetic preparations. In a study examining tyrosine kinase activity 
(toward angiotensin-I) in insulin receptor preparations made from rat 
skeletal muscle, Burant et al. (42) described reduced activity in diabetic 
preparations at incubation temperatures of 25° and 4°C with insulin- 
agarose bound (purified) and non-immobilized (partially purified) insulin 
receptors, respectively. This finding would suggest that the observed 
inconsistencies between phosphorylation studies performed at 4°C (30,39, 
45,48,49) and 20-24°C (29,35,49) could have been the result of "contami¬ 
nating" activities (ATPases/ phosphatases?) which are active at ambient 
temperatures. These activities are apparently absent in more highly 
purified preparations of the insulin receptor (43,56,74,79). 
CTP has been employed as a competitive inhibitor of contaminating 
ATPases (31,36,38,50,71,74). In the majority of these studies (36,38,50,71,74), 
the addition of CTP led to enhanced insulin receptor tyrosine kinase 
activity. In light of these results CTP was added to the tyrosine kinase 
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reaction mixture in an attempt to eliminate variability and enhance the 
minimal insulin response by inhibiting ATPases that might be copurifying 
with the insulin receptor. Unexpectedly, CTP actually reduced insulin- 
stimulated tyrosine kinase activity in both control and diabetic preparations 
(Table 2). The mechanism of this effect was not further investigated, but 
since CTP has not been shown previously to inhibit the insulin receptor 
tyrosine kinase, a direct effect is unlikely. 
A number of studies have used vanadate in an attempt to inhibit 
contaminating phosphotyrosine phosphatases and ATPases (31,33,36,38, 
47,49,50,71,74,79). A majority of studies (31,38,49,50,71,74) found vanadate to 
be effective in this role, so the effect of vanadate was evaluated in the 
present study. Vanadate was shown to enhance insulin-stimulated 
tyrosine kinase activity in both microsomal (Figure 5) and PM (Figure 6) 
preparations suggesting the presence of ATPases/phosphatases sensitive to 
vanadate. In microsomes, vanadate actually enhanced tyrosine kinase 
activity to a greater extent in control preparations than in diabetic 
preparations suggesting more ATPase/phosphatase activity copurified with 
the control group. 
Experiments that examined the time course of insulin-stimulated 
tyrosine kinase activity with and without vanadate yielded similar results. 
In microsomes without vanadate (Figure 7), kinase activity plateaued 
earlier in the control than in the diabetic group, but when vanadate was 
added kinase activity was nearly linear for up to 20 minutes in both groups. 
These findings suggested again the presence of vanadate-sensitive 
ATPases/phosphatases in microsomal preparations with more activity in 
the control group. In PM preparations, in the presence of vanadate 
insulin-stimulated kinase activity was nearly linear over the first 10 
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minutes of incubation but plateaued in control preparations by 20 minutes, 
again implicating more ATPase/phosphatase activity or a greater 
vanadate-insensitive component in the control group. 
With the previous experiments implicating the presence of 
contaminating ATPases/phosphatases, the actual combined activities of 
these enzymes were assessed by measuring their by-product, 32p_ 
orthophosphate (from the hydrolysis of [y32p]ATP by ATPases or from 
dephosphorylation of ^^P-labelled. insulin receptor by phosphatases). These 
data confirmed the existence of contaminating ATPases/phosphatases in 
both microsomal (Figure 11) and PM (Figure 12) preparations. ATPase/ 
phosphatase activities were found to be greater in control than in diabetic 
preparations from both membrane compartments. This activity was also 
significantly inhibited by vanadate in all preparations, however to a lesser 
degree in the PM preparations, suggesting a vanadate-insensitive 
component. 
In a continuation of the present study, this laboratory evaluated 
dephosphorylation of 32p_iakeiied (3-subunits of the insulin receptor and 
found this activity to be higher in insulin receptor preparations from 
control PM compared to diabetic PM (90). This result is in contrast to 
previous studies in which microsomal phosphatase activity was found to be 
unchanged (54) or increased (55) by diabetes. A residual vanadate- 
insensitive phosphatase was also detected, and preliminary 
characterization showed it to be a phosphotyrosine phosphatase (90). 
Previous studies that have isolated phosphatases capable of dephosphory- 
lating the phosphorylated forms of the insulin receptor (52-57,59) or poly 
Glu/Tyr(4:l) (64,67) have shown this activity to be inhibited by vanadate at 
doses (1 mM) equal to or less than that used in the present and following 
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(90) studies. However, vanadate-insensitive phosphotyrosine phosphatases 
have been isolated (77,78). The function of the phosphatases and ATPases 
present in the current study and their alterations in diabetes merit further 
investigation. 
The extent of ATPase/phosphatase contamination found in insulin 
receptor preparations from microsomes appears to be determined by the 
amount of protein used in incubations to measure insulin receptor tyrosine 
kinase activity. For example, in microsomes (Figure 11) the ATPase/ 
phosphatase activity based on 32p.orthophosphate formation per unit 
insulin binding is 64% higher in the control than in the diabetic prepa¬ 
rations but only 30% higher based on activity per unit protein. This finding 
may explain the observation of Kadowaki et al. (43) who reported ATP 
hydrolysis to be higher (12.5% compared to 4.5% at 4°C) in microsomal 
insulin receptor preparations from control rats compared to those from 
diabetic rats. The fact that ATPase/phosphatase activity seems to vary with 
protein content stresses the importance of monitoring this copurifying 
activity when comparing preparations of equal binding but different protein 
content (e.g. microsomal preparations). 
Insulin receptor tyrosine kinase activity was examined when ATP 
concentration was not limiting and in the presence of vanadate in order to 
eliminate the effect of copurifying ATPases/phosphatases. In microsomal 
preparations (Figure 13), double reciprocal plot analysis of the data revealed 
a Vmax for the diabetic group which was 42% less than that of the control 
group in agreement with a continuation of the present study by this 
laboratory (56% reduction in the diabetic Vmax) (90). This finding of 
reduced tyrosine kinase activity in the diabetic group confirmed the results 
of a majority of previous studies evaluating tyrosine kinase activity at sub- 
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maximal (11,30,32,34, 39,41,43,45,48,49) and maximal (11,32,34) ATP 
concentrations. 
Double reciprocal plot analysis of data from PM preparations (Figure 
14) found a Vmax for the diabetic group which was 43% less than that of the 
control group. This finding was in agreement with the continuation of the 
present study by this laboratory (38% reduction in diabetic Vmax) (90) but 
was in contrast to the previous study by this laboratory (44) which found 
that diabetes did not affect insulin-stimulated insulin receptor autophos¬ 
phorylation. A possible explanation is that autophosphorylation and 
phosphorylation of other substrates are uncoupled in diabetes. On the other 
hand, this discrepancy might be explained by the intersecting lines of the 
double reciprocal plot (Figure 14). In the presence of the lowest concen¬ 
tration of ATP tested (25 pM), the insulin-sensitive tyrosine kinase activity 
was found to be 77% higher in insulin receptor preparations from diabetic 
rats, whereas at Vmax, tyrosine kinase activity was 43% lower in the 
diabetic group. The greater vanadate-insensitive ATPase activity observed 
in the control preparation (discussed above, Figure 12) probably contributed 
greatly to these observations. At low ATP concentrations, the disparate 
ATPase/phosphatase activities would reduce the measurable kinase activity 
significantly more in the control than in the diabetic preparations so that 
the diabetic kinase activity would seem greater than or equal to the control 
activity. At high ATP concentrations, the effect of ATPase/phosphatase 
activity would be relatively insignificant, and the true kinase activities of 
the insulin receptors would be observed. 
In light of these findings, the ATPases/phosphatases present in PM 
preparations but not completely inhibited by vanadate probably confounded 
the earlier experiments (Figure 6) conducted at submaximal ATP (100 pM) 
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in which it was concluded that PM tyrosine kinase activity is higher in the 
diabetic group. Similarly, these ATPases/phosphatases probably also 
confounded the results of the previous study by this laboratory (44) because 
it was conducted in the presence of only 25 pM [y32p]ATP and in the 
absence of vanadate. In fact, when this experiment was repeated by this 
laboratory in the presence of 100 pM fy^pjATP and vanadate, auto¬ 
phosphorylation was reduced by 52% in the diabetic group (90). These 
observations also emphasize the need to perform phosphorylation 
measurements at multiple ATP concentrations, especially when using PM 
preparations. 
Lineweaver-Burke analysis also allowed the determination of the Km 
of ATP for the insulin receptor tyrosine kinase. In both microsomal 
(Figure 13) and PM (Figure 14) preparations, the Km's for ATP were 
reduced in the diabetic groups in comparison to the control group. 
Although the reduction in Km in diabetic preparations might have been 
due to changes in the structure or conformation of the insulin receptor (no 
changes have been observed [41]), reduced levels of ATPase/phosphatase 
activities in the diabetic preparations are more likely to have been 
responsible for the current observations. Indeed, the higher Km (ATP) 
seen in the PM control preparation suggests that a greater degree of 
vanadate-insensitive ATPases were present. 
Lin (76) has described the presence of a calcium/magnesium ecto- 
ATPase in detergent solubilized preparations of rat hepatic PM. This 
activity is not identical to membrane ion-pump ATPases based on 
insensitivity to specific ion-pump ATPase inhibitors, such as vanadate, and 
the lack of substrate specificity toward ATP. Although the function of this 
ecto-ATPase is not known, Lin (76) suggested that it may function to 
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regulate extracellular ATP levels. An ATPase/phosphatase activity was 
found in this study in both PM and microsomal insulin receptor prepa¬ 
rations and found to be only partially suppressible in the former by 1 mM 
vanadate. Further studies (90) have shown the presence of a nucleotide 
hydrolyzing activity in PM preparations capable of utilizing GTP, 
insensitive to vanadate (1 mM), EGTA, and ouabain, and dependent on 
magnesium or calcium for activation. Indeed, the ATP hydrolyzing activity 
in the present study may be related to Lin's ecto-ATPase (76) and seems to 
be altered by diabetes in some way that reduces its concentration and/or 
activity. 
The results of the present study and its continuation by this 
laboratory (90) seem to suggest that a defect in insulin receptor function at 
the level of the tyrosine kinase is present in diabetes and cannot be 
explained by changes in ATPase/phosphatase activity. In fact, more 
ATPase/phosphatase activity was detected in the control preparations 
implying that insulin receptor tyrosine kinase activity is reduced by 
diabetes even more than observed in the present study because of the 
presence of vanadate-insensitive ATPase/phosphatase activity. The present 
study is the first to show that this reduction of tyrosine kinase activity by 
diabetes is also present in PM insulin receptors. 
The mechanism(s) underlying this alteration in insulin receptor 
function by diabetes is unclear. One investigator (36) has suggested that 
diabetes increased the Km (ATP) of the insulin receptor kinase, but the 
results of the present study show the Km (ATP) to be reduced by diabetes. 
Other studies have suggested that changes in phosphotyrosine phospha¬ 
tases are responsible, but the current and following (90) studies found 
greater phosphatase activity in the control group. Structural or confor- 
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mational changes in the insulin receptor secondary to alterations in 
maturation or glycosylation have been suggested (36,40,41) hut not been 
confirmed (40). There is some evidence (11,14,29,36) for a defective auto¬ 
activation cascade in the diabetic insulin receptor leading to inadequate 
signal coupling. Another theory is that diabetes increases serine 
phosphorylation of the insulin receptor causing it to become inactivated 
(36,40,41,80). Further research is still needed to define the mechanism(s) 
underlying the diabetes-induced alterations in the insulin receptor tyrosine 
kinase before new methods of therapy and prevention can be developed for 
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